Date: 1998–1999 Time span: One year Diagnoses: 75% depression 10% schizophrenia 6% schizoaffective 8% bipolar 0.5% residual Gender: 63% women Age, year groups: 6%, 15–24 32%, 25–44 28%, 45–64 33%, >65 Licensing: All facilities providing ECT must be licensed Mandatory: Monthly reports Other: High use in age group >65 years TPR: 3.99–4.44 EAR: Inhibitors,research,lifescience,medical 33.03–36.26 iP: 8% No information Western Australia (R) Teh SPC (Teh et al. 2005) Study: Register data from Mental Health Information System of Western Australia and records from state psychiatric hospitals N= 1175 estimated ECT treated in five-year period. N= 622 ECT treated within State psychiatric facilities

Inhibitors,research,lifescience,medical from 1988 to 2001. Date: 1997–2001 Time span: Five years Diagnoses: 43% affective psychoses 35% depression 4% bipolar 2% schizophrenia 2% other Gender: 65% women Age, year groups: 2%, 0–18 71%, 19–64 27%, >65 Ethnicity: 1% aboriginality 99% nonaboriginality Involuntary: 21% treated involuntary at least once (within State facilities) Other: Upward trend Inhibitors,research,lifescience,medical in TPR and number of ECT AZD0530 recipients in five-year period TPR: 0.8 (1997) 1.3 (1998) 1.2 (1999) 1.6 (2000) 1.4 (2001) iP: 1.0–1.7% No information Australia, Sydney, New South Wales (C) Lamont S (Lamont et al. 2011) Study: Audit of ECT service provision at metropolitan teaching hospital in Sydney

with 28 inpatients bed, serving a population of 260,000. N= 43 ECT-treated patients Date: November 2007– November 2008 Time span: One year Diagnoses: Inhibitors,research,lifescience,medical 67% depression 9% schizoaffective 14% schizophrenia 5% bipolar 5% schizophrenia catatonic type,

neuroleptic malignant syndrome Indication: 25% resistant to antidepressants: 21% resistant to antipsychotics/lithium: 21% suicidal 9% Inhibitors,research,lifescience,medical previous response 7% life-saving intervention 5% severe retardation 5% too distressed to wait drug response 5% patient preference 2% psychosis Gender: 71% women Age, year groups: 5%, 15–24 37%, 25–44 30%, 45–64 Methisazone 14%, 65–74 14%, >75 Condition: 40% voluntary 60% involuntary (Mental Health Review Tribunal consent) TRP: 1.8 AvE, women: 10.2 AvE, men: 8 Modified Anesthesia: Propofol Sucxamethonium Device: Thymatron System IV Type: Brief pulse Placement: 35% RUL 40% BL 23% Both RUL and BL View it in a separate window *TPR: treated person rate = persons ECT treated per 10,000 resident population per year. *EAR: ECT administration rate = no. of ECTs administered per 10,000 resident population. *iP: inpatient prevalence = proportion (percent, %) ECT treated among inpatient population. *AvE: average number of ECTs administered per patient (in a session or course). **C-ECT: continuation-ECT. **A-ECT: ambulatory-ECT. Table C2 Africa (N= 3).